Skip to Main Content
Contribute Try STAT+ Today

An advocacy group has asked the National Institutes of Health to investigate whether several patents held by Aegerion Pharmaceuticals failed to disclose federal funding for grants that were used to develop a pricey cholesterol treatment.

In its request, the advocacy group cited a federal database showing six patents were awarded to the University of Pennsylvania, where an academic researcher used NIH grants to develop a drug called Juxtapid, which was later licensed to Aegerion Pharmaceuticals. The school has received more than $68 million in grants for research led by Dr. Daniel Rader, who chairs the genetics department at the Perelman School of Medicine, and at least $293,000 pertained to his work on Juxtapid, according to Knowledge Ecology International, the advocacy group.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.